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CASE REPORT
Malignant Triton Tumor of the Brachial Plexus Invading the
Left Thoracic Inlet
A Rare Differential Diagnosis of Pancoast Tumor
Jo Dartnell, BSc, MRCS,* John Pilling, FRCS (CTh),* Rosalie Ferner, MD, FRCP,†
Paul Cane, BMedSci, FRCP(Path),‡ and Loïc Lang-Lazdunski, MD, PhD, FRCS*
Malignant triton tumor is a divergent malignant peripheral nerve
sheath tumor with rhabdomyoblastic differentiation. We report a
case of malignant triton tumor arising in the brachial plexus of a
28-year-old women with neurofibromatosis type 1. Fluorodeoxyglu-
cose-positron emission tomography-computed tomography before
excision demonstrated a tumor with a maximum standard uptake
value of 21 at 4 hours postinjection. The patient underwent complete
excision of the tumor through median sternotomy and left supracla-
vicular approach. Adjuvant radiotherapy and chemotherapy were
planned but the patient died of metastatic disease within 3 months of
surgical resection.
Key Words: Malignant peripheral nerve sheath tumor, Triton tu-
mor, Neurofibromatosis 1, Pancoast tumor.
(J Thorac Oncol. 2009;4: 135–137)
Malignant Triton tumor (MTT) is a rare type of malignantperipheral nerve sheath tumor (MPNST) with divergent
differentiation and is identified histologically by the finding
of rhabdomyoblasts among malignant Schwann cells in a
tumor arising from a peripheral nerve.1 In 1932 Masson
described the first case of a MTT in a patient with Von
Recklinghausen disease (now known as Neurofibromatosis 1
[NF1]).2 However, it is now believed that only two thirds of
MTT arise in patients with NF1.3,4 The prognosis of this rare
and highly malignant tumor is poor and optimal treatment
remains unclear. In this article we present a patient with NF1
who was found to have a MTT arising in the brachial plexus
causing Pancoast tumor.
Clinical Summary
A 28-year-old women presented with a 15-year history
of progressive left shoulder pain and 5-month history of an
enlarging supraclavicular mass and reduced sensation with
‘claw’ deformity of her left hand. A clinical diagnosis of NF1
was made due to the presence of multiple cafe´-au-lait spots
and axillary and inguinal freckling. She had no significant
family history, but two of her three children were also
diagnosed with NF1 at that time. A tender left supraclavicular
mass was palpable and complete radiculopathy of C8/T1 was
demonstrable. Her left radial and ulnar pulses were absent.
Chest radiograph revealed a large mass in the left thoracic
inlet. Chest computed tomography (CT) and magnetic resonance
imaging were suggestive of a large tumor involving the brachial
plexus and left subclavian artery (Figure 1). Fluorodeoxyglu-
cose-positron emission tomography-CT (18FDG PET-CT) dem-
onstrated increased uptake of FDG within the tumor with a
maximum standardized uptake value (SUVmax) of 21 at 4 hours
postinjection (Figure 2). It was clear that the tumor involved the
brachial plexus and surrounding mediastinal structures but its
origin was not certain. CT-guided biopsy of the mass was
performed and histopathology raised the suspicion of a MPNST.
The patient underwent resection of the tumor en bloc
with the lower cord of the brachial plexus via a median
sternotomy with supraclavicular extension and excision of the
first rib (Figure 3). The left subclavian artery and phrenic
nerve were dissected from the tumor and preserved. The
patient had an uneventful postoperative recovery and was
discharged after 5 days. There was no postoperative Horner
syndrome, the left radial pulse was palpable and no C5–7
neurologic deficit could be demonstrated, although she had
persistent severe weakness and sensory loss in C8/T1.
Histopathological examination of the specimen re-
vealed a 135  90  60 mm tumor that contained spindle
cells and scattered large round cells with eosinophilic cyto-
plasm (Figure 4). On immunochemical staining, the spindle
cells showed patchy focal staining for S100 and the larger
eosinophilic cells showed positivity for desmin and myogenin
(muscle-specific antibodies). The resection margins, local
lymph nodes and rib showed no evidence of malignancy. The
final diagnosis was of a Triton tumor.
In the light of the aggressive nature of MTT, plans were
made for the patient to receive adjuvant radiotherapy. A
planning CT at 6 weeks showed multiple pleural and pulmo-
nary metastases. The patient was referred for palliative care
and died 3 months postoperatively.
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DISCUSSION
MTT is a rare tumor with less than 100 cases docu-
mented in the English literature and less than 10 cases arising
in the chest.5 MTT is an interesting neurogenic tumor in
which the neural component is thought to induce skeletal
muscle production. This process was known to occur follow-
ing Locatelli’s experiment with the Triton salamander, where
he showed that by implanting a sciatic nerve in the
salamander’s back, growth of accessory limbs containing
both neural and muscular tissue could be stimulated.6 Mas-
son, in 1932, first described the malignant potential of this in
the form of a MTT, naming it after Locatelli’s Salamander.2
The diagnosis of MTT is usually made following sur-
gical resection as the areas containing rhabdomyoblasts may
be a small proportion of the total tumor and may not be
represented in preoperative biopsies. On light microscopy,
spindle Schwann cells and larger rounder rhabdomyoblasts
are seen. Immunohistochemical staining for S-100 protein is
used to identify the Schwann cell component. A variety of
muscle-specific antibodies can be used to show rhabdomyo-
blastic differentiation, in this case myogenin and desmin were
both positive.1–3
Patients with NF1 have a 10% life time risk of devel-
oping malignant change in plexiform neurofibromas, partic-
ularly deep-seated lesions and those involving the brachial
and lumbo-sacral plexus. These individuals require lifelong
monitoring by clinicians conversant with NF1. Our patient
had been complaining of left shoulder pain for 15 years
before she was referred to us for diagnosis or investigations.
It is likely that the Triton tumor arose from a pre-existing
neurofibroma in her brachial plexus.
The value of 18FDG PET CT as a diagnostic tool for
NF1 associated MPNST has been recognized recently. FDG
PET CT has a sensitivity of 0.89 and specificity of 0.95 in
NF1 patients undergoing investigation for symptomatic plex-
iform neurofibromas.7 The SUVmax may help distinguish
between benign and malignant tumors, but cannot accurately
predict the grade of malignancy.7 In a recent study from our
institution, at 200 minutes post injection the mean SUVmax
of malignant tumors was 5.4 whereas the mean SUVmax for
benign tumors was 1.54 with an overlap between malignant
and benign tumors in the range of 2.7 to 3.3.8 In our patient
a SUVmax of 21 at 4 hours, was highly suggestive of
malignant transformation. In a study of 16 NF1 patients with
known MPNST Brenner et al.9 found that patients with a
MPNST and an SUV greater than 3 had a significantly shorter
median survival than those with a SUV less than 3.
Two thirds of patients with MTT have NF1. They are
predominantly male and under 35 with lesions arising from
the head and neck. The remainder of the patients are gener-
ally older and female with tumors arising on their trunk. For
both groups the prognosis is poor and overall survival is 33%
at 2 years and 12% at 5 years.4 As MTT is a very aggressive
tumor, behaving like a high grade sarcoma, it is believed that
to obtain the best outcome a full surgical resection with as
wide a margin as possible is vital. Complete resection of
FIGURE 1. Magnetic resonance imaging (MRI) and com-
puted tomography (CT) showing the large neurogenic tu-
mor arising from the thoracic inlet in close contact with the
subclavian vessels and aortic arch but not invading the left
upper lobe.
FIGURE 2. Positron emission tomography-computed tomog-
raphy (PET-CT) showing a large 9  7.3 cm Fluorodeoxyglu-
cose (FDG) avid tumor in the left upper thoracic cavity.
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tumors arising from the brachial plexus is difficult but tech-
nically feasible in 79% of cases with acceptable morbidity
and mortality.10 It usually provides good symptom control.
An anterior supraclavicular approach to the brachial plexus is
the most common technique and, in this case, was combined
with excision of the first rib, to enable control of the subcla-
vian vessels. A median sternotomy was also performed to
allow access to the mediastinum, aortic arch, and left upper
lobe. After surgery, it is generally accepted that, if fit enough,
patients should receive adjuvant radiotherapy as MTTs have
a high rate of local recurrence.11 Systemic chemotherapy is
instituted if there is evidence of metastatic disease.
One of us has reported a patient with MTT of the
posterior mediastinum who survived without relapse for more
than 8 years following complete resection and adjuvant ra-
diotherapy.12 However, a recent case report showed local
relapse 3 months following excision and adjuvant radiother-
apy in a young patient with NF1.5 We have recently treated a
42-year-old man with neurofibromatosis who had a large
MTT completely excised from his chest wall, relapsed and
died within a year following adjuvant radiotherapy.
Based on our experience and in view of the literature,
we suggest that MTTs arising in the chest are treated as high
grade soft tissue sarcomas. The diagnostic and prognostic
value of 18FDG-PET-CT may help select patients for multi-
modality therapy or palliative treatment.
ACKNOWLEDGMENTS
We are grateful to Dr. Michael O’Doherty from the
Clinical PET Centre at St. Thomas’ Hospital for help with
FDG PET CT.
REFERENCES
1. Woodruff JM, Chernik NL, Smith MC, et al. Peripheral nerve tumours
with rhabdosarcomatous differentiation (malignant “Triton” tumours).
Cancer 1973;32:426–439.
2. Masson P. Recklinghausen’s Neurofibromatosis. Sensory Neuromas and
Motor Neuromas. New York: International Press, 1932:2.
3. Daimaru Y, Hashimoto H, Enjoli M. Malignant Triton Tumours. A
Clinicopathologic and immunohistochemical study of nine cases. Hu-
man Pathology 1984;15:768–778.
4. Brooks, JS, Freeman M, Enterline HT. Malignant “Triton” tumours.
Natural history and immunohistochemistry of nine new cases with
literature review. Cancer 1985;55:2543–2549.
5. Cano JR, Algar FJ, Alvarez A, et al. A Triton tumour of the left
sympathetic nerve. Interact Cardiovasc Thorac Surg 2006;5:790–791.
6. Locatelli P. Formation de membres surnumeraires. CR Assoc. des
Anatomistes. 20e Reunion. Turin 1925:279–282 (In French).
7. Ferner RE, Golding JF, Smith M, et al. [18F] 2-fluoro-2-deoxy-D-
glucose positron emission tomography (FDG PET) as a diagnostic tool
for neurofibromatosis 1 (NF1) associated malignant peripheral nerve
sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol
2008;19:390–394.
8. Ferner RE, Lucas JD, O’Doherty MJ, et al. Evaluation of (18) fluoro-
deoxyglucose positron emission tomography in the detection of malig-
nant peripheral nerve sheath tumours arising from within plexiform
neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry
2000;68:353–357.
9. Brenner W, Friedrich RE, Gawad KA, et al. Prognostic relevance of
FDG PET in patients with neurofibromatosis type-1 and malignant
peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006;
33:428–432.
10. Ganju A, Rossen N, Kline DG, et al. Outcomes in a consecutive series
of 111 surgically treated plexal tumours: a review of the experience at
the Louisiana State University Health Sciences Center. J Neurosurg
2001;95:51–60.
11. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malig-
nant peripheral nerve sheath tumor: molecular pathogenesis and current
management considerations. J Surg Oncol 2008;97:340–349.
12. Lang-Lazdunski L, Pons F, Jancovici R. Malignant Triton tumor of the
posterior medistinum: Prolonged survival after radical resection. Ann
Thorac Surg 2003;75:1645–1648.
FIGURE 3. The surgically resected specimen (371 g; 135 
90  60 mm) completely resected en bloc with mediastinal tissue,
scalene muscles and the lower cord of the brachial plexus.
FIGURE 4. Histopathology (hematoxylin and eosin  100).
Arrows pointing to the scattered large round cells with eo-
sinophilic cytoplasm representing rhabdomyoblasts among
the spindle cells.
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